Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11505616 Binding molecules to CD38 and PD-L1

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Biomunex Pharmaceuticals

Current Assignee

Biomunex Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

November 22, 2022

Patent Application Number

16088181

Date Filed

March 27, 2017

Patent Citations

US Patent 10815310 Multispecific antigen binding fragments and multispecific antibodies derived therefrom comprising mutant CH1 and CL-kappa domains

US Patent 10633456 Vista antigen-binding molecules

US Patent 10662241 HER3 antigen-binding molecules

US Patent 11046776 Multivalent and multiepitopic antibodies having agonistic activity and methods of use

Patent Primary Examiner

Jessica H Roark

CPC Code

The present invention relates to a bispecific molecule comprising at least one anti-CD38 domain and at leak one anti-PD-L1 domain, which are capable of simultaneous binding to CD38 and PD-L1 antigens, respectively.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11505616 Binding molecules to CD38 and PD-L1

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool